Today, Boehringer Ingelheim received FDA approval for Cyltezo®, its biosimilar to AbbVie’s Humira® (adalimumab). Cyltezo® is approved for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, and plaque psoriasis. This is the second adalimumab biosimilar approved by the FDA. Amgen’s Amjevita® was the first adalimumab biosimilar to receive FDA approval (September 23, 2016), but no adalimumab biosimilar is on the US market yet.
AbbVie recently filed a complaint for patent infringement under the BPCIA against Boehringer Ingelheim based on its filing of the aBLA for Cyltezo® as we reported here.
The post FDA Approves Boehringer Ingelheim’s Adalimumab Biosimilar appeared first on Goodwin Procter BioSimilars Blog.